On the basis of sustained long-term results, sacral neuromodulation (SNM) has become a widely adopted and established treatment modality for overactive bladder, non-obstructive urinary retention and faecal incontinence [1-6]. Since its approval for clinical use in 1994 more than 325 000 patients have been treated worldwide with several further potential indications under investigation [7]. In the majority (about 80%) of patients undergoing implantation, SNM leads to a clinically significant reduction in symptoms [1,8-10]. However, it is recognized that, even within this group, a